Recently, Baiyang Medical Group announced its intention to sell its 40.0465% equity stake in Wivita, a move seen as a strategic step to refocus on core businesses and optimize its asset portfolio. Wivita is a company specializing in the research, development, and sales of nutritional health products and was once a key part of Baiyang’s expansion into the broader health sector. However, amid evolving market dynamics and a strategic realignment, Baiyang has decided to divest non-core assets to concentrate resources on its strengths—such as brand operations, digital marketing, and pharmaceutical distribution. This equity transfer is expected not only to improve overall operational efficiency but also generate investment gains and strengthen cash flow. Analysts note that the transaction reflects Baiyang’s accelerated shift toward higher-value, more synergistic business lines, reinforcing its position as a leading commercialization platform for pharmaceutical brands in China. Following the deal, Wivita’s controlling stake may change hands, though its day-to-day operations are unlikely to be significantly affected. Going forward, Baiyang Medical will continue advancing its integrated strategy centered on ‘brand + channel + data’ to drive high-quality, sustainable growth.
近日，百洋医药集团宣布拟出售其所持有的五维康（Wivita）40.0465%股权。此举被视为公司聚焦核心业务、优化资产结构的重要战略调整。五维康是一家专注于营养健康产品的研发与销售的企业，曾是百洋医药在大健康领域布局的关键一环。然而，随着市场环境变化及公司战略重心的转移，百洋医药决定剥离非核心资产，以集中资源发展其优势板块，如品牌运营、数字化营销和医药流通等。此次股权转让不仅有助于提升公司整体运营效率，还可能带来一定的投资收益，增强现金流。分析人士指出，该交易反映出百洋医药正加速向高附加值、高协同性的业务方向转型，进一步夯实其在中国医药品牌商业化平台中的领先地位。交易完成后，五维康的控制权或将发生变更，但其原有业务运营预计不会受到重大影响。未来，百洋医药将继续围绕“品牌+渠道+数据”三位一体的战略，推动高质量可持续发展。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/8117.html